JAAHA Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeffreys, A. B.
Right arrow Articles by Lucroy, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeffreys, A. B.
Right arrow Articles by Lucroy, M. D.
Journal of the American Animal Hospital Association 41:221-226 (2005)
© 2005 American Animal Hospital Association

Retrospective Study

Influence of Asparaginase on a Combination Chemotherapy Protocol for Canine Multicentric Lymphoma

Antonella Borgatti Jeffreys, DVM, Deborah W. Knapp, DVM, MS, Diplomate ACVIM (Oncology), William W. Carlton, DVM, Diplomate ACVP, Rosanne M. Thomas, RVT, Patty L. Bonney, BS, RVT, A. deGortari, MVZ and Michael D. Lucroy, DVM, MS, Diplomate ACVIM (Oncology)

From the Departments of Veterinary Clinical Sciences (Jeffreys, Knapp, Thomas, Bonney, deGortari, Lucroy) and Veterinary Pathobiology (Carlton), School of Veterinary Medicine, and the Purdue Cancer Center (Knapp, Lucroy), Purdue University, West Lafayette, Indiana 47907.

Address all correspondence to Dr. Lucroy.

Combination chemotherapy is superior to single-agent chemotherapy for treating canine lymphoma, but the effect of each drug on efficacy remains unknown. By comparing 34 dogs treated with a modified cyclophosphamide, vincristine, prednisone (COP) chemotherapy protocol and 42 dogs given asparaginase in the induction phase of the same protocol, the effect of asparaginase on the chemotherapeutic protocol was determined. Both groups were compared based on clinical response at 2 weeks and 6 weeks, and on the progression-free interval. Asparaginase did not significantly increase the likelihood of a clinical remission or prolong the initial progression-free interval in the dogs studied.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Animal Hospital Association.